| Literature DB >> 30189851 |
Hao Sun1,2, Yiting Shen1, Guangwen Luo1, Yuepiao Cai3, Zheng Xiang4.
Abstract
BACKGROUND: Target identification is necessary for the comprehensive inference of the mechanism of action of a compound. The application of computational methods to predict the targets of bioactive compounds saves cost and time in drug research and development. Therefore, we designed an integrated strategy consisting of ligand-protein docking, network analysis, enrichment analysis, and an experimental surface plasmon resonance (SPR) method to identify and validate new targets, and then used enriched pathways to elucidate the underlying pharmacological mechanisms. Here, we used rhein, a compound with various pharmacological activities, as an example to find some of its previously unknown targets and to determine its pharmacological activity.Entities:
Keywords: Enrichment analysis; Ligand-protein docking; Network analysis; Rhein; SPR; Target identification
Mesh:
Substances:
Year: 2018 PMID: 30189851 PMCID: PMC6127921 DOI: 10.1186/s12859-018-2346-4
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Fig. 1The strategy of the target identification
Fig. 2Network construction of rhein targets. a Rhein target protein–protein interaction network (PPI). b Extended rhein target PPI network (EPPI). In these networks, each node is a protein, and an edge indicates that two proteins interact with each other. Purple nodes represent known rhein targets; green nodes represent potential rhein targets; light blue nodes represent extended adjacent proteins of rhein targets
Fig. 3The receiver-operator characteristic (ROC) curves of five topological parameters in the extended protein–protein interaction (EPPI) network
Area under the ROC curve
| Test Result Variable(s) | Area | Std. Errora | Asymptotic Sig.b | Asymptotic 95% Confidence Interval | |
|---|---|---|---|---|---|
| Lower Bound | Upper Bound | ||||
| Betweenness Centrality | .710 | .090 | .033 | .533 | .886 |
| Degree | .690 | .093 | .054 | .508 | .871 |
| Closeness Centrality | .627 | .109 | .198 | .413 | .841 |
| Clustering Coefficient | .383 | .068 | .234 | .250 | .515 |
| Topological Coefficient | .248 | .059 | .010 | .133 | .363 |
aUnder the nonparametric assumption
bNull hypothesis: true area = 0.5
21 selected targets based on network analysis
| Target Name | Gene Symbol | Target Type | Be Enriched or Not | Betweenness Centrality |
|---|---|---|---|---|
| Heat shock protein 90 kDa alpha (cytosolic), class A member 1 | HSP90AA1 | Candidate | Yes | 0.04743 |
| Epidermal growth factor receptor | EGFR | Candidate | Yes | 0.02710 |
| Cyclin-dependent kinase 2 | CDK2 | Candidate | Yes | 0.01959 |
| Albumin | ALB | Candidate | No | 0.01653 |
| Glycogen synthase kinase 3 beta | GSK3B | Candidate | Yes | 0.01317 |
| V-rel reticuloendotheliosis viral oncogene homolog A (avian) | RELA | Known | Yes | 0.00777 |
| Mitogen-activated protein kinase 14 | MAPK14 | Candidate | Yes | 0.00765 |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | NFKB1 | Known | Yes | 0.00364 |
| Dipeptidyl-peptidase 4 | DPP4 | Candidate | No | 0.00348 |
| Mitogen-activated protein kinase 8 | MAPK8 | Candidate | Yes | 0.00321 |
| Lymphocyte-specific protein tyrosine kinase | LCK | Candidate | Yes | 0.00279 |
| Cyclin-dependent kinase 6 | CDK6 | Candidate | Yes | 0.00277 |
| RAB5A, member RAS oncogene family | RAB5A | Candidate | No | 0.00275 |
| Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 | SERPINA1 | Candidate | No | 0.00244 |
| Cathepsin B | CTSB | Candidate | No | 0.00241 |
| Caspase 3, apoptosis-related cysteine peptidase | CASP3 | Known | Yes | 0.00238 |
| K(lysine) acetyltransferase 2B | KAT2B | Candidate | No | 0.00237 |
| Retinoic acid receptor, alpha | RARA | Known | Yes | 0.00198 |
| Vascular endothelial growth factor A | VEGFA | Known | Yes | 0.00178 |
| Caspase 8, apoptosis-related cysteine peptidase | CASP8 | Known | Yes | 0.00165 |
| Retinoid X receptor, alpha | RXRA | Known | Yes | 0.00163 |
Fig. 4The surface plasmon resonance (SPR) results of the interaction between LCK and rhein. Increased concentration of LCK protein showed a trend of increased binding with rhein; the equilibrium dissociation constant (K) was 1.060 × 10− 6 M
Fig. 5Diagrammatic sketch of the idea for network analysis and enrichment analysis. In this diagrammatic sketch, plane a represents the target protein–protein interaction (PPI) of one bioactive compound, targets of which were mapped to a biological network (plane b). In fact, the target extended PPI (EPPI) of this bioactive compound is the network with broken circle in plane b. According to the importance of nodes in the network, plane c was selected from the EPPI via network analysis. The plane d represents the enriched pathway of proteins in plane c. Thus, the potential targets of this bioactive compound in plane d could be considered to be candidate targets
Fig. 6The integrated network of enrichment pathways of rhein targets. This pathway was constructed via manually extracting the biological process which is related to enriched targets of rhein from the KEGG pathway. The main body of a biological process was extracted if a rhein target was in this biological process. The protein marked by star is the rhein target. Purple and green stars represent known and candidate targets, respectively